CTCFL

Across TCGA pan-cancer cohorts, CTCFL Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CTCFL data layer compared with 19 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher CTCFL Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CTCFL expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, UCEC, and SARC are the cancer types where CTCFL Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.082	0.792	<.001	18	view →
UCEC	DFS	Median	All	0.954	0.612	.004	14	view →
SARC	OS	Median	All	0.085	0.839	<.001	12	view →
STAD	OS	Median	IV	0.001	0.544	<.001	12	view →
LUAD	OS	Median	III,IV	0.144	0.674	<.001	12	view →
SKCM	DFS	Median	III,IV	0.164	0.660	.005	7	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CTCFL–COAD (OS)

Open the COAD breakdown →